8-K: Chimerix Secures $30 Million Loan Facility and Regains Nasdaq Compliance

Chimerix, Inc. has entered into a $30 million loan agreement, regained compliance with Nasdaq listing rules, and submitted a new drug application to the FDA.

Summary

• Chimerix has secured a loan facility of up to $30 million with Silicon Valley Bank, available in two tranches.
• The first tranche of $20 million is available until February 28, 2026, and the second tranche of $10 million is available until February 28, 2027, subject to lender approval.
• The loan is interest-only until March 1, 2026, potentially extending to March 1, 2027, if certain cash proceeds are met.
• The interest rate is a floating rate, the greater of the Prime Rate or 7.0%.
• A final payment of 4.0% of the funded loan amount is due upon termination of the facility.
• Prepayment fees apply if the loan is paid off early, ranging from 1.0% to 3.0%, but are waived if refinanced with the same lender.
• The loan is secured by a first lien on most of Chimerix's assets, excluding intellectual property.
• Chimerix has also issued a warrant to the lender to purchase up to 149,253 shares of common stock at $2.68 per share.
• The company has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for 10 consecutive days.
• Chimerix has submitted a new drug application (NDA) to the FDA for dordaviprone, seeking accelerated approval and priority review, and has applied for a Rare Pediatric Disease Priority Review Voucher.
• If priority review is granted, a potential PDUFA action date is expected in the third quarter of 2025.

Sentiment

Score: 7

Explanation: The document contains positive news regarding financing and regulatory progress, but also includes risks associated with the loan and future compliance. The sentiment is moderately positive.

Positives

• The $30 million loan facility provides Chimerix with additional working capital.
• Regaining Nasdaq compliance removes the risk of delisting.
• The NDA submission for dordaviprone is a significant step forward for the company's drug development program.
• The potential for a priority review voucher could expedite the approval process.

Negatives

• The loan is secured by a first lien on most of the company's assets, excluding intellectual property.
• The loan has a floating interest rate, which could increase if the Prime Rate rises.
• Prepayment fees apply if the loan is paid off early, unless refinanced with the same lender.
• The company has no obligation to draw down any amount under the Credit Facility, and did not draw down any amount on the Effective Date.

Risks

• There is no guarantee that Chimerix will maintain compliance with Nasdaq listing rules in the future.
• The FDA may not grant priority review for the NDA.
• The company may not receive the Rare Pediatric Disease Priority Review Voucher.
• The company may not be able to achieve the cash proceeds required to extend the interest-only period of the loan.
• The company may not be able to draw down the full amount of the loan facility.

Future Outlook

The company's future performance is subject to risks and uncertainties, including market conditions and the success of its drug development programs. The company is seeking accelerated approval for dordaviprone and is awaiting a potential PDUFA action date in the third quarter of 2025.

Management Comments

• The company has submitted a complete new drug application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States.
• The company has requested Priority Review for the NDA and applied for a Rare Pediatric Disease Priority Review Voucher (PRV) as part of this NDA submission.

Industry Context

The loan facility provides Chimerix with financial flexibility to continue its drug development efforts. The NDA submission for dordaviprone is a key milestone in the company's pipeline. The company's ability to regain Nasdaq compliance is important for maintaining investor confidence.

Comparison to Industry Standards

• The loan terms, including interest rates and prepayment penalties, are generally consistent with those seen in the biotech industry for companies of similar size and stage.
• The use of a warrant as part of the financing package is a common practice in the biotech sector.
• The NDA submission and pursuit of priority review are standard procedures for companies seeking to bring new drugs to market.
• Regaining Nasdaq compliance is a critical step for any listed company, and Chimerix's success in this area is a positive sign.

Stakeholder Impact

• Shareholders will be impacted by the new loan facility and the potential dilution from the warrant.
• Employees will benefit from the company's improved financial position and continued operations.
• Patients may benefit from the potential approval of dordaviprone.
• Creditors will be impacted by the new loan agreement.

Next Steps

• The company will continue to work with the FDA on the review of its NDA for dordaviprone.
• The company may draw down on the loan facility as needed for working capital and general corporate purposes.
• The company will need to maintain compliance with Nasdaq listing rules.

Key Dates

Keywords

loan facility, Nasdaq compliance, NDA submission, dordaviprone, priority review, Rare Pediatric Disease Priority Review Voucher, Silicon Valley Bank, warrant, drug development, biotechnology